[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-001", "question": "A 68-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide presents with progressive dyspnea and fatigue. He has no chest pain or fever. His oxygen saturation is 88% on room air. CT pulmonary angiography shows no pulmonary embolism, but reveals diffuse ground-glass opacities with peripheral sparing. Bronchoalveolar lavage shows lymphocytic predominance with CD4:CD8 ratio of 0.3. Which of the following is the most appropriate next step in management?", "options": ["Discontinue enzalutamide and initiate high-dose corticosteroids", "Initiate empiric broad-spectrum antibiotics for atypical pneumonia", "Add abiraterone to his current regimen and continue enzalutamide", "Perform transbronchial biopsy to rule out lymphangitic carcinomatosis", "Start therapeutic-dose low-molecular-weight heparin for occult pulmonary embolism"], "answer": "A", "answer_index": 0, "explanation": "This presentation is classic for enzalutamide-induced interstitial pneumonitis, which typically presents with subacute dyspnea, ground-glass opacities on CT, and a lymphocytic BAL with low CD4:CD8 ratio. Immediate discontinuation of the offending agent and initiation of corticosteroids is the standard management. Antibiotics are not indicated without infectious signs, and adding abiraterone would exacerbate the drug-induced lung injury.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation of progressive dyspnea, hypoxemia, and diffuse ground-glass opacities on CT in a patient taking enzalutamide is suggestive of drug-induced interstitial lung disease (ILD) / pneumonitis. While rare (<1% of patients), cases of ILD/pneumonitis have been reported with enzalutamide use, and regulatory guidelines recommend discontinuing the drug if ILD is suspected.\n\nThe key diagnostic clue provided is the bronchoalveolar lavage (BAL) finding of a lymphocytic predominance with a low CD4:CD8 ratio (0.3). A low CD4:CD8 ratio (<1.0) is characteristic of hypersensitivity pneumonitis (HP) or HP-like drug reactions (in contrast to sarcoidosis or some other drug reactions which typically have a high ratio). This points strongly toward a hypersensitivity reaction to the medication.\n\nGiven the patient's hypoxia (88% saturation), the condition is severe (Grade 3), necessitating immediate discontinuation of the offending agent and the initiation of systemic corticosteroids to suppress the inflammation.\n\nOption B is less likely given the lack of fever and the specific BAL findings. Option C is incorrect as continuing the offending agent would worsen the condition. Option D involves an invasive procedure that is not the most appropriate immediate management step when the clinical picture strongly points to a drug reaction that requires cessation of the drug. Option E is incorrect because the CTPA has already ruled out pulmonary embolism.\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-002", "question": "A 4-month-old previously healthy infant presents with acute onset of irritability, vomiting, and lethargy. Physical examination reveals a bulging anterior fontanelle, retinal hemorrhages, and no focal neurologic deficits. Non-contrast head CT shows bilateral subdural hematomas of different ages. The infant's coagulation studies and metabolic panel are normal. Which of the following additional findings would most strongly support a diagnosis of glutaric aciduria type 1 rather than non-accidental trauma?", "options": ["Metaphyseal corner fractures on skeletal survey", "Elevated serum ammonia level", "Frontotemporal atrophy with widened Sylvian fissures on MRI", "Subarachnoid hemorrhage extending into the posterior fossa", "Elevated urine organic acids showing 3-hydroxyglutaric aciduria"], "answer": "E", "answer_index": 4, "explanation": "While glutaric aciduria type 1 can mimic non-accidental trauma with acute encephalopathy and subdural hematomas, the definitive diagnosis requires demonstration of elevated urine organic acids, specifically 3-hydroxyglutaric aciduria. Frontotemporal atrophy (option C) is a characteristic neuroimaging finding but is not diagnostic. Metaphyseal fractures strongly suggest abuse, while elevated ammonia suggests a different metabolic disorder.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The clinical presentation of the 4-month-old infant—irritability, vomiting, lethargy, bulging fontanelle, retinal hemorrhages, and subdural hematomas (SDH) of different ages—is highly concerning for non-accidental trauma (NAT), also known as abusive head trauma (AHT). However, Glutaric Aciduria Type 1 (GA1) is a well-known metabolic \"mimic\" of AHT.\n\nGA1 is caused by a deficiency in glutaryl-CoA dehydrogenase. The disorder typically presents with macrocephaly and can have acute encephalopathic crises triggered by illness or stress.\n\nLet's evaluate the options to see which most strongly supports GA1 over NAT:\n\n*   A. Metaphyseal corner fractures: These are highly specific for abuse (classic metaphyseal lesions). Their presence would strongly support NAT, not GA1.\n*   B. Elevated serum ammonia level: While mild hyperammonemia can occur during metabolic crises in GA1, it is non-specific and more characteristic of urea cycle disorders or other organic acidemias (like propionic or methylmalonic acidemia). It does not specifically identify GA1.\n*   C. Frontotemporal atrophy with widened Sylvian fissures on MRI: This is the hallmark neuroimaging finding in GA1 (often called \"bat-wing\" appearance). The widening of the Sylvian fissures and anterior subarachnoid spaces stretches the bridging veins, predisposing them to rupture with minimal or no trauma, leading to subdural hematomas. While this finding is highly suggestive and provides the anatomical mechanism for the SDH in GA1, it is an imaging sign that requires confirmation. Furthermore, benign external hydrocephalus can have a similar appearance.\n*   D. Subarachnoid hemorrhage extending into the posterior fossa: This is a nonspecific finding often associated with trauma.\n*   E. Elevated urine organic acids showing 3-hydroxyglutaric aciduria: The detection of 3-hydroxyglutaric acid (and glutaric acid) in the urine is the biochemical hallmark and diagnostic confirmation of Glutaric Aciduria Type 1. While imaging (Option C) raises the suspicion and explains the susceptibility to SDH, the identification of the specific metabolic derangement (Option E) is definitive proof of the disease. In a context where one must distinguish between abuse and a metabolic mimic, the presence of the pathognomonic metabolite provides the strongest evidence for the metabolic diagnosis.\n\nTherefore, the definitive lab finding is the strongest support.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-003", "question": "A 55-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who failed CAR T-cell therapy 3 months ago presents with new-onset confusion and myoclonus. MRI brain shows symmetric diffusion restriction in the bilateral thalami, basal ganglia, and cerebral cortex. EEG demonstrates periodic sharp wave complexes. CSF shows 12 white cells/mm³ (90% lymphocytes), normal glucose, and elevated protein at 80 mg/dL. Which of the following is the most likely causative agent?", "options": ["Tafasitamab", "Polatuzumab vedotin", "Tisagenlecleucel", "Blinatumomab", "Brentuximab vedotin"], "answer": "C", "answer_index": 2, "explanation": "This presentation is classic for CAR T-cell therapy-related immune effector cell-associated neurotoxicity syndrome (ICANS), which can occur weeks to months after treatment. The MRI pattern of symmetric deep gray matter and cortical involvement with corresponding EEG findings is characteristic. Tisagenlecleucel is a CD19-directed CAR T-cell therapy used in DLBCL. The other agents are monoclonal antibodies or antibody-drug conjugates not typically associated with this specific delayed neurotoxicity pattern.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation of new-onset confusion, myoclonus, symmetric diffusion restriction in the bilateral thalami, basal ganglia, and cerebral cortex (cortical ribboning), and periodic sharp wave complexes on EEG is highly suggestive of Creutzfeldt-Jakob Disease (CJD) or a syndrome mimicking it.\n\nIn the context of a patient with DLBCL who has received CAR T-cell therapy (Tisagenlecleucel), the most likely diagnosis is Human Herpesvirus 6 (HHV-6) encephalitis. HHV-6 reactivation is a known complication of cellular therapies (especially CAR T-cell therapy and HCT). While it classically presents with limbic encephalitis (medial temporal lobe hyperintensity), it can present with extra-limbic involvement, including the thalami and basal ganglia, and can mimic CJD clinically (myoclonus, profound confusion/amnesia) and electrographically (periodic discharges). The specific \"CJD-like\" MRI pattern (cortical and deep gray matter restriction) and EEG findings in an immunocompromised host post-CAR T are characteristic of this severe viral encephalitis.\n\nWhile Blinatumomab (Option D) is a salvage therapy that causes frequent neurotoxicity (ICANS), the MRI findings in ICANS are typically normal or show mild T2 hyperintensities/edema, rather than the specific symmetric diffusion restriction in the cortex and deep gray matter described here. Polatuzumab (Option B) causes neuropathy. Tafasitamab (Option A) has a low neurotoxicity profile. Brentuximab (Option E) is associated with PML (white matter changes), not gray matter diffusion restriction.\n\nTherefore, the condition is likely HHV-6 encephalitis, a complication associated with the profound immunosuppression and T-cell therapy context of Tisagenlecleucel.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-004", "question": "A critically ill patient with septic shock on norepinephrine (0.3 mcg/kg/min) and vasopressin (0.03 units/min) develops refractory hypotension. Transthoracic echocardiogram shows a hyperdynamic left ventricle with collapsing mitral inflow pattern. Which of the following interventions is most likely to improve hemodynamics without increasing myocardial oxygen demand?", "options": ["Initiate dobutamine infusion at 5 mcg/kg/min", "Add phenylephrine infusion to target MAP >65 mmHg", "Administer 500 mL 5% albumin bolus", "Start angiotensin II infusion at 20 ng/kg/min", "Increase norepinephrine to 0.5 mcg/kg/min"], "answer": "D", "answer_index": 3, "explanation": "The echocardiographic findings suggest distributive shock with relative hypovolemia. Angiotensin II acts via AT1 receptors to cause vasoconstriction without significant inotropic effects, making it ideal for this scenario without increasing myocardial oxygen demand. Dobutamine increases myocardial demand, phenylephrine causes pure alpha-agonism with potential reflex bradycardia, fluid bolus may be insufficient in vasoplegic shock, and increasing norepinephrine adds beta-1 effects that increase oxygen consumption.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical scenario describes a patient with septic shock who remains hypotensive despite significant vasopressor support (norepinephrine and vasopressin). The underlying physiology of septic shock typically involves vasodilation and relative or absolute hypovolemia due to capillary leak and venous pooling.\n\nThe key diagnostic information is the transthoracic echocardiogram finding of a hyperdynamic left ventricle (LV).\n1.  Interpretation: A hyperdynamic LV (high ejection fraction, vigorous contraction) in a hypotensive patient strongly suggests intravascular volume depletion. The heart is contracting vigorously against a low stroke volume (\"empty tank\").\n2.  Collapsing patterns: While \"collapsing mitral inflow\" is less standard terminology than \"collapsing IVC,\" in this context, it—along with end-systolic cavity obliteration (kissing papillary muscles)—indicates severe underfilling and preload responsiveness.\n3.  Physiology of Interventions:\n    *   Volume Expansion (Option C): Administering fluids (such as albumin or crystalloids) restores preload. By utilizing the Frank-Starling mechanism, this increases stroke volume and cardiac output. Consequently, the sympathetic drive (tachycardia and hypercontractility) often decreases, leading to stabilized or reduced myocardial oxygen demand (MVO2) while improving blood pressure.\n    *   Inotropes (Option A): Dobutamine increases myocardial contractility and heart rate. In a patient with an already hyperdynamic heart, this would dangerously increase MVO2, potentially precipitate arrhythmias, or worsen dynamic left ventricular outflow tract (LVOT) obstruction.\n    *   Vasopressors (Options B, D, E): Phenylephrine, Angiotensin II, and increasing Norepinephrine primarily increase afterload (systemic vascular resistance). Increasing afterload against a hypovolemic, hyperdynamic ventricle increases wall stress and MVO2 without addressing the primary defect (low preload). While they may raise blood pressure, they can reduce cardiac output in a hypovolemic heart and compromise tissue perfusion.\n\nTherefore, the most appropriate intervention to improve hemodynamics (by increasing stroke volume) while minimizing myocardial oxygen demand (by reducing the need for compensatory hyperdynamism and tachycardia) is volume resuscitation.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-005", "question": "A 7-year-old boy presents with acute cerebellar ataxia following varicella infection 2 weeks prior. MRI shows T2 hyperintensity restricted to the cerebellar hemispheres. CSF demonstrates 15 lymphocytes/mm³, normal glucose, and elevated IgG index. Which of the following autoantibodies is most specific for this condition?", "options": ["Anti-GAD65", "Anti-Hu", "Anti-Yo", "Anti-Tr/DNER", "Anti-mGluR1"], "answer": "D", "answer_index": 3, "explanation": "Post-varicella acute cerebellar ataxia is associated with anti-Tr/DNER (delta/notch-like epidermal growth factor-related receptor) antibodies in a significant proportion of cases. This antibody is highly specific for paraneoplastic cerebellar degeneration in Hodgkin lymphoma but also occurs in post-infectious contexts. Anti-Yo and anti-Hu are associated with gynecological/breast cancers and small cell lung cancer respectively. Anti-mGluR1 is seen in Hodgkin-related ataxia, while anti-GAD65 is associated with stiff-person syndrome.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The clinical presentation describes a 7-year-old boy with acute cerebellar ataxia following a varicella (chickenpox) infection. The MRI findings (cerebellar hyperintensity) and CSF findings (pleocytosis, elevated IgG index) are consistent with acute cerebellitis or post-infectious cerebellar ataxia.\n\nThis condition is widely believed to be caused by an autoimmune mechanism involving molecular mimicry between viral proteins and antigens on cerebellar Purkinje cells. While the most specifically associated antibody in the literature for post-varicella ataxia is anti-glutamate receptor delta 2 (anti-GluRδ2) (not listed), anti-mGluR1 (anti-metabotropic glutamate receptor 1) is the correct choice among the provided options for the following reasons:\n\n1.  Pathophysiology: Anti-mGluR1 antibodies target surface antigens on Purkinje cells, leading to neuronal dysfunction that can be reversible (consistent with the acute and often self-limiting nature of post-infectious ataxia), whereas Anti-Hu and Anti-Yo are associated with intracellular antigens and irreversible cytotoxic T-cell mediated neuronal destruction (classic paraneoplastic syndromes).\n2.  Demographics and Etiology: Anti-Hu, Anti-Yo, and Anti-Tr generally occur in adults with specific malignancies (small cell lung cancer, gynecologic cancers, Hodgkin lymphoma). Anti-mGluR1 has been described in children and adults with autoimmune cerebellar ataxia, which can be idiopathic or post-infectious, distinct from the classic paraneoplastic presentations.\n3.  Receptor Class: Both GluRδ2 (the classic VZV target) and mGluR1 are glutamate receptors located on cerebellar Purkinje cells. In the context of examining autoimmune ataxia involving Purkinje cell surface antibodies, Anti-mGluR1 is the standard representative in many testing panels and questions when GluRδ2 is not an option.\n\nAnti-GAD65 (Option A) is associated with Stiff-Person Syndrome and chronic cerebellar ataxia, often with polyendocrine autoimmunity (Type 1 Diabetes), rather than an acute post-viral presentation.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-006", "question": "A 42-year-old woman with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) achieves complete morphological remission after induction chemotherapy. Minimal residual disease (MRD) testing by flow cytometry shows 0.01% blasts. Which of the following factors would most strongly indicate proceeding to allogeneic hematopoietic stem cell transplantation in first complete remission rather than continuing with chemotherapy plus a tyrosine kinase inhibitor?", "options": ["Presence of IKZF1 deletion", "Age >40 years", "MRD positivity after consolidation therapy", "White blood cell count >30,000/μL at diagnosis", "Presence of additional cytogenetic abnormalities besides t(9;22)"], "answer": "C", "answer_index": 2, "explanation": "In Ph+ ALL, MRD positivity after consolidation therapy is the strongest predictor of poor outcome with chemotherapy/TKI alone and is a clear indication for allogeneic transplantation in first remission. While age >40, high WBC, IKZF1 deletion, and additional abnormalities are adverse prognostic factors, contemporary TKI-based regimens can overcome many of these. Persistent MRD after intensive therapy indicates resistant disease requiring transplant for cure.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "In the era of tyrosine kinase inhibitors (TKIs), the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has evolved. Historically, allogeneic hematopoietic stem cell transplantation (HSCT) was the standard for all eligible patients in the first complete remission (CR1). However, with the use of potent TKIs (such as ponatinib) combined with chemotherapy, patients who achieve a deep molecular response (complete molecular remission, or undetectable MRD) have outcomes that may be comparable to those achieving HSCT, without the associated transplant-related morbidity and mortality.\n\nConsequently, the decision to proceed to allo-HSCT in CR1 is increasingly guided by the minimal residual disease (MRD) response.\n\n*   A. Presence of *IKZF1* deletion: While *IKZF1* deletions (and the \"IKZF1-plus\" phenotype) are associated with worse prognosis and higher relapse rates in Ph+ ALL, the prognostic impact is often modulated by the depth of the response to TKI therapy. MRD status is generally considered a stronger predictor of outcome than baseline genetic markers.\n*   B. Age >40 years: While older age is a risk factor for poor tolerability and outcomes, it is not a specific indication for transplant over chemotherapy; in fact, increasing age often increases the risks associated with transplant.\n*   C. MRD positivity after consolidation therapy: This is the most critical factor. Persistent minimal residual disease (failure to achieve complete molecular remission, often assessed at 3 months/post-consolidation) indicates disease resistance to the TKI+chemotherapy regimen and is the strongest predictor of relapse. Current guidelines strongly recommend that patients who remain MRD-positive proceed to allo-HSCT.\n*   D. White blood cell count >30,000/μL at diagnosis: Baseline WBC is a traditional risk factor but is less relevant in Ph+ ALL treated with TKIs compared to the response to therapy (MRD).\n*   E. Presence of additional cytogenetic abnormalities: While additional chromosomal abnormalities can confer a worse prognosis, their impact is secondary to the achievement of a deep molecular response (MRD negativity).\n\nTherefore, persistent MRD positivity is the strongest indication to switch strategy from chemotherapy+TKI maintenance to allo-HSCT to prevent relapse.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-007", "question": "A 65-year-old man with atrial fibrillation on apixaban presents with acute onset of aphasia and right hemiparesis. CT head shows a 3 cm left MCA territory infarct with no hemorrhage. Last apixaban dose was 4 hours ago. NIH Stroke Scale is 18. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator immediately", "Give 4-factor prothrombin complex concentrate followed by tPA", "Perform emergent mechanical thrombectomy without thrombolysis", "Administer andexanet alfa followed by mechanical thrombectomy", "Give idarucizumab empirically followed by mechanical thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "For large vessel occlusion strokes in patients on direct oral anticoagulants (DOACs) with recent dosing, mechanical thrombectomy without thrombolysis is recommended due to the increased risk of hemorrhagic transformation with tPA. Andexanet alfa is a reversal agent for factor Xa inhibitors but is not routinely recommended prior to thrombectomy unless there is life-threatening bleeding. Idarucizumab is for dabigatran reversal. PCC before tPA still carries bleeding risk and delays intervention.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with a severe acute ischemic stroke (NIHSS 18) and a CT scan showing early ischemic changes in the left middle cerebral artery (MCA) territory. The key factor in decision-making is his medication history: he is taking apixaban (a direct factor Xa inhibitor) and the last dose was taken 4 hours ago.\n\n1.  Intravenous tPA (Alteplase): According to AHA/ASA guidelines, IV tPA is generally contraindicated in patients who have received a dose of a direct oral anticoagulant (DOAC) like apixaban within the last 48 hours, unless specialized coagulation assays (e.g., anti-Xa activity) show no anticoagulant effect. Since the dose was 4 hours ago, the anticoagulant effect is near peak. Therefore, Option A is incorrect because of the high risk of intracranial hemorrhage.\n\n2.  Mechanical Thrombectomy (MT): Recent ingestion of anticoagulants is not a contraindication for mechanical thrombectomy. In patients presenting with large vessel occlusion (LVO) who are ineligible for IV tPA due to anticoagulation status, the standard of care is to proceed directly to mechanical thrombectomy. Option C correctly describes this course of action.\n\n3.  Reversal Agents:\n    *   Andexanet alfa (Option D): While this is a reversal agent for apixaban, it is indicated for life-threatening bleeding. Its use to reverse anticoagulation solely to facilitate stroke intervention (thrombectomy or tPA) is not established as standard care and carries thrombotic risks. Reversal is not required for the endovascular procedure.\n    *   Idarucizumab (Option E): This is the reversal agent for dabigatran, not apixaban.\n    *   PCC (Option B): Prothrombin complex concentrate is generally used for warfarin reversal or emergent bleeding management, not typically to facilitate tPA in ischemic stroke due to pro-thrombotic risks.\n\nTherefore, the most appropriate intervention is to bypass enzymatic thrombolysis and proceed to mechanical removal of the clot.\n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-008", "question": "A 3-year-old child with DiGeorge syndrome (22q11.2 deletion) presents with hypocalcemic seizures. Correction of calcium with intravenous calcium gluconate and calcitriol is initiated. Which of the following immunologic parameters, if present, would be an absolute contraindication to live viral vaccination?", "options": ["CD4+ T cell count <500 cells/μL", "Absent thymic shadow on chest radiograph", "Low but detectable T cell receptor excision circles (TRECs)", "Severely reduced proliferative response to phytohemagglutinin", "Complete absence of CD3+ T cells by flow cytometry"], "answer": "E", "answer_index": 4, "explanation": "Complete absence of CD3+ T cells indicates severe combined immunodeficiency (SCID) phenotype within DiGeorge spectrum, which is an absolute contraindication to live vaccines due to risk of disseminated infection. Reduced proliferative responses (option D) indicate functional impairment but not complete absence. Low TRECs suggest poor thymic output but not necessarily SCID. CD4 count and thymic shadow are not definitive contraindications alone.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation of the 3-year-old child (hypocalcemic seizures, 22q11.2 deletion) is consistent with DiGeorge syndrome. Ideally, the immune system status of patients with DiGeorge syndrome ranges from normal T-cell function to severe immunodeficiency (Complete DiGeorge syndrome).\n\nLive viral vaccines (such as MMR and Varicella) are generally contraindicated in patients with severe T-cell immunodeficiency due to the risk of uncontrolled viral replication and disseminated infection.\n\nAccording to the ACIP (Advisory Committee on Immunization Practices) and AAP (American Academy of Pediatrics) guidelines (Red Book) regarding vaccination in children with DiGeorge syndrome:\n*   Live viral vaccines can be administered if:\n    1.  The CD4+ T-cell count is > 500 cells/μL.\n    2.  There is evidence of adequate T-cell function (normal mitogen response).\n\nConsequently, a CD4+ T cell count < 500 cells/μL is considered evidence of severe immunosuppression in this context and serves as an absolute contraindication to the administration of live viral vaccines.\n\nLet's evaluate the other options:\n*   B. Absent thymic shadow: This is a common finding in DiGeorge syndrome (due to thymic aplasia or hypoplasia) but does not correlate perfectly with immune function. Many children with an absent thymic shadow have \"partial\" DiGeorge syndrome with sufficient T-cell counts and function to be vaccinated safely.\n*   C. Low but detectable TRECs: T-cell receptor excision circles (TRECs) are markers of recent thymic output. Low levels are expected in DiGeorge syndrome. \"Detectable\" implies some thymic activity, which is often consistent with partial DiGeorge syndrome and does not automatically preclude vaccination.\n*   D. Severely reduced proliferative response to phytohemagglutinin (PHA): While a severely reduced mitogen response is a contraindication, the specific numerical threshold of CD4 < 500 is the most widely cited and clinically utilized cutoff parameter defining the safety limit for this specific syndrome in board examinations and guidelines. The count is the primary screen.\n*   E. Complete absence of CD3+ T cells: This represents \"Complete DiGeorge Syndrome\" (SCID phenotype). While this is definitely an absolute contraindication, it is a subset of the contraindication criteria. Option A (CD4 < 500) encompasses both patients with complete absence (0 cells) and those with severe lymphopenia (e.g., 200 cells) who also must not be vaccinated. Therefore, A is the broader and more defining guideline parameter for the contraindication.\n\nThe definition of severe immunodeficiency precluding live vaccination in a child of this age (1-5 years) is typically a CD4 count < 500 cells/μL (CDC Immunologic Category 3).\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-009", "question": "A patient with glioblastoma on temozolomide and dexamethasone develops progressive headache, visual changes, and diabetes insipidus. MRI shows thickening and enhancement of the pituitary stalk with loss of the posterior pituitary bright spot. CSF cytology is negative. Which of the following findings would most strongly support a diagnosis of lymphocytic hypophysitis over pituitary metastasis?", "options": ["Presence of anti-pituitary antibodies", "Elevated CSF beta-2 transferrin", "Simultaneous involvement of the pineal gland", "Rapid improvement with high-dose corticosteroids", "Association with other autoimmune endocrine deficiencies"], "answer": "E", "answer_index": 4, "explanation": "Lymphocytic hypophysitis frequently presents with other autoimmune endocrine deficiencies (thyroiditis, adrenalitis, diabetes mellitus type 1), while pituitary metastases typically occur in isolation. Anti-pituitary antibodies have poor sensitivity/specificity. CSF beta-2 transferrin indicates CSF leak. Pineal involvement suggests germinoma. Steroid responsiveness occurs in both conditions but is more dramatic in hypophysitis; however, association with other autoimmune conditions is more specific.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This question asks for the finding that would most strongly distinguish lymphocytic hypophysitis (LH) from pituitary metastasis in a patient with glioblastoma.\n\n1.  Analyze the Clinical Picture: The patient has a high-grade malignancy (glioblastoma) and presents with diabetes insipidus (DI), headache, and visual changes. MRI shows a thickened, enhancing pituitary stalk. This presentation (infundibulo-hypophysitis) is consistent with both lymphocytic hypophysitis and pituitary metastasis (which frequently affects the pituitary stalk and posterior lobe, causing DI). The patient is currently on temozolomide and dexamethasone.\n\n2.  Evaluate the Differentials:\n    *   Pituitary Metastasis: Common in cancer patients. Glioblastoma can spread via CSF (drop metastases), although systemic metastases are rare. Symptoms like DI and stalk thickening are classic. Metastases (solid tumors) typically do not exhibit significant mass reduction with corticosteroids, although peritumoral edema might improve.\n    *   Lymphocytic Hypophysitis: An autoimmune inflammatory condition. It is characterized by lymphocytic infiltration. It is strongly associated with pregnancy/postpartum (not mentioned here) and other autoimmune diseases. A hallmark feature of LH (and other inflammatory masses like IgG4-related disease or sarcoidosis) is a rapid and dramatic reduction in size in response to high-dose corticosteroids.\n\n3.  Analyze the Options as Discriminators:\n    *   A. Presence of anti-pituitary antibodies: While specific to an autoimmune etiology, current assays for anti-pituitary antibodies generally lack sensitivity and standardization (commercial variability). Their absence does not rule out LH, and their clinical utility is debated.\n    *   B. Elevated CSF beta-2 transferrin: This is a marker for CSF leakage (rhinorrhea/otorrhea), not relevant to distinguishing mass lesions.\n    *   C. Simultaneous involvement of the pineal gland: This is characteristic of intracranial germinomas, not lymphocytic hypophysitis.\n    *   D. Rapid improvement with high-dose corticosteroids: This constitutes a diagnostic trial. Lymphocytic hypophysitis is an inflammatory process that is highly sensitive to lymphocytotoxic doses of steroids. In contrast, metastatic carcinomas or gliomas (solid tumors) generally do not shrink significantly or rapidly in mass size with steroids (though edema may resolve). Therefore, a demonstrated rapid improvement in mass size and symptoms with high-dose steroids is the strongest functional evidence supporting an inflammatory etiology (LH) over a neoplastic one (metastasis). Note: While the patient is currently on dexamethasone, the option specifies \"Rapid improvement with high-dose corticosteroids,\" implying a successful response to a therapeutic/diagnostic pulse dose, which serves as the distinguishing feature. If the patient worsened on maintenance steroids, it suggests metastasis, but if they *did* improve with high-dose steroids (the hypothetical finding in the option), it would support LH.\n    *   E. Association with other autoimmune endocrine deficiencies: LH is associated with other autoimmune conditions in ~20-50% of cases. Finding concurrent autoimmune disease (e.g., Hashimoto's thyroiditis) increases the pre-test probability of LH. However, a patient with glioblastoma could coincidentally have autoimmune thyroiditis. This association is supportive (circumstantial) but not as definitive/mechanistic as the physiological response of the lesion to treatment (Option D).\n\n4.  Conclusion: The most specific behavioral characteristic distinguishing a lymphoid/inflammatory lesion from a solid tumor metastasis is the response to high-dose corticosteroids. This \"steroid trial\" is often used clinically when biopsy is not feasible.\n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-010", "question": "A neonate born at 32 weeks gestation develops necrotizing enterocolitis (NEC) on day 10 of life. During laparotomy, approximately 40% of the small bowel appears necrotic. Which of the following intraoperative findings would mandate creation of a high jejunostomy rather than primary anastomosis?", "options": ["Involvement of the ileocecal valve", "Necrosis extending to within 5 cm of the ligament of Treitz", "Presence of pneumatosis intestinalis in the remaining bowel", "Concurrent isolated perforation of the gastric fundus", "Development of abdominal compartment syndrome during surgery"], "answer": "B", "answer_index": 1, "explanation": "Necrosis extending to within 5 cm of the ligament of Treitz indicates near-total small bowel loss, requiring high jejunostomy to preserve the maximal possible length of viable bowel for future adaptation and prevent anastomotic leakage in compromised tissue. Ileocecal valve involvement is important for absorption but doesn't dictate anastomosis vs ostomy. Pneumatosis may be present in non-necrotic bowel. Gastric perforation is managed separately. Abdominal compartment syndrome may require temporary closure but not necessarily jejunostomy.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This question addresses the surgical decision-making in necrotizing enterocolitis (NEC), specifically the choice between primary anastomosis and enterostomy (stoma creation).\n\nAnalysis of the Clinical Scenario:\nThe patient is a neonate with NEC undergoing laparotomy. A significant portion (40%) of the small bowel is necrotic. The surgeon must decide between connecting the bowel ends (primary anastomosis) or bringing the bowel out as a stoma (jejunostomy). Primary anastomosis is generally preferred to preserve bowel length and avoid the complications of a high-output stoma, provided the conditions are safe.\n\nAnalysis of the Options:\n\n*   A. Involvement of the ileocecal valve: While the loss of the ileocecal valve worsens the prognosis for short bowel syndrome, it does not mandate a stoma. An ileocolic anastomosis can be performed if the remaining bowel ends are healthy.\n*   B. Necrosis extending to within 5 cm of the ligament of Treitz: This implies a resection of the substantial majority of the small bowel, leaving a very short segment of proximal jejunum. Creating a stoma this proximal (high jejunostomy) results in unmanageable fluid and electrolyte losses and is extremely difficult to pouch. In such \"ultra-short gut\" scenarios, many surgeons actually prefer a primary anastomosis (if the distal bowel/colon is viable) to utilize the colon's absorptive capacity, rather than creating a stoma that guarantees nutritional failure and severe dehydration. Thus, this finding often argues *against* a stoma, or at least does not mandate it over anastomosis if anastomosis is technically feasible.\n*   C. Presence of pneumatosis intestinalis in the remaining bowel: Primary anastomosis relies on healthy, vascularized tissue for healing. Pneumatosis intestinalis in the \"remaining bowel\" (the segments that would be sutured) indicates active disease, ischemia, and inflammation in the bowel wall. Suturing diseased bowel carries an unacceptably high risk of anastomotic leak and dehiscence. Therefore, if the resection margins or the remaining segments intended for anastomosis show pneumatosis, primary anastomosis is contraindicated, and diversion (enterostomy) is mandated.\n*   D. Concurrent isolated perforation of the gastric fundus: This is a separate injury typically treated with primary repair (gastrorrhaphy). While it complicates the case, it does not strictly dictate the management of the small bowel resection (stoma vs. anastomosis) in the same way local tissue viability does.\n*   E. Development of abdominal compartment syndrome during surgery: If the abdomen cannot be closed due to visceral edema (compartment syndrome), the standard of care is a \"damage control\" approach: the bowel ends are stapled off (\"clip and drop\"), and a temporary silo is placed. While this precludes an immediate anastomosis, it does not typically result in the immediate maturation of a high jejunostomy (stoma creation is difficult in open abdomens). Often, the decision for stoma vs. anastomosis is deferred to a second-look operation. However, Option C represents the specific tissue-factor contraindication that forces the decision toward diversion (stoma) rather than restoration of continuity (anastomosis) during the decisive reconstruction phase.\n\nConclusion:\nThe absolute contraindication to primary anastomosis in NEC is the presence of disease (ischemia, inflammation, pneumatosis) at the resection margins or in the remaining bowel segments to be joined.\n\nThe answer is (C)"}]